- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01165385
Study With Pazopanib in Combination With Cisplatin (CDDP) in Patients With Advanced Solid Tumors (PACIFIK)
An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors
The aim of this research is to evaluate the potential interest of an association of Pazopanib, a multi-tyrosine kinase inhibitor, and cisplatin.
As cisplatin has marketing approval for several cancers (ovarian, testicle, bladder, esophagus, endometrium, lung, stomach, head and neck cancer (HNC)), and in order to have a rapid evaluation of this combination, we will evaluate the combination in any patient whose tumors is known to be sensible to cisplatin (except tumors at risk of bleeding).
This study is a classical phase 1 trial of pazopanib and 3-weekly cisplatin association. It will allow for optimal dose selection and pharmacokinetic analysis. It is planed to include around 38 patients, enriching the optimal tolerated regimen (OTR) level only with a cohort of triple negative breast cancer patients. If the association is proven to be feasible, we will then move to a specific phase II study in triple negative breast cancer patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of the study is to determine the dose limiting toxicities (DLT) and the optimal tolerated regimen (OTR) which are both safety criteria evaluated upon the NCI CTC-AE system version 4.0.
Efficacy is not the primary objective; however the anti-tumor activity of the pazopanib/cisplatin combination will be carried out by the determination of the objective response rate according to RECIST criteria version 1.1.
The objective response is defined as either a complete response (CR) or partial response (PR), assessed either by CT Scan and/or MRI and/or bone Scan, performed at baseline and every 6 weeks.
This is an open-label, non-randomized, dose escalation and pharmacokinetic, phase I study pazopanib with cisplatin in patients with relapsed or refractory solid tumors (except tumors at risk of bleeding) for whom the selected combined chemotherapy is indicated or is a reasonable option (as per tumor characteristics and previous treatments).
All eligible patients entering the study will receive daily oral pazopanib, supplied as 200 mg aqueous film-coated tablets and intravenous cisplatin every three weeks. Doses of both compounds will be adjusted according to the reached dose level.
The treatment will continue until the development of unacceptable toxicity or evidence of disease progression or until patient's / investigator's decision of withdrawal.
All patients who received at least on dose of the study drug will be followed for survival outcome.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Caen, France, 14076
- Centre François Baclesse
-
Dijon, France, 21079
- Centre Georges François Leclerc
-
Lyon, France, 69373 cedex 08
- Centre Léon Bérard
-
Nantes Saint Herblain, France, 44805
- Centre Rene Gauducheau
-
Paris, France, 75248
- Institut Curie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main Inclusion Criteria:
Documented metastatic solid malignancies for patients who are candidate to receive a cisplatin based regimen.
- During the dose seeking procedure : ALL solid tumors
- During the Optimal Tolerated Regimen validation procedure : ONLY HER2-RH- breast cancer
- Measurable or evaluable disease
- WHO performance status ≤ 1
- Negative dipstick proteinuria test or if positive proteinuria <1g/24h. If proteinuria appears ≥ 2+ on routine dipstick testing, patients must undergo a 24H -urine collection and demonstrate proteinuria < 1g/24H
- Corrected QT interval (QTc) ≤ 480 msecs using Bazett's formula
Main Exclusion Criteria:
- Prior treatment with cisplatin reaching a cumulative dose> 300 mg/m2
- HER2 positive breast cancer
- Patients at high risk of bleeding
- Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product
- calcium and magnesium levels inferior to standard levels (measured within 14 days before the first pazopanib dose) and potassium levels inferior to standard levels (measured within 72 hours before the first pazopanib dose)
- Patients with other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study
- Hearing impairment/tinnitus > or = grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pazopanib and Cisplatin
|
60, 75 or 100 mg/m2 , day 1 - 3 weekly
Other Names:
400 mg, 600 mg or 800 mg/day, daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determination of the Optimal Tolerated Regimen (OTR) based on the occurrence of Dose Limiting Toxicities
Time Frame: cycles 1 and 2
|
cycles 1 and 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response - Overall Objective response rate - Clinical Benefit Rate
Time Frame: At baseline and every 6 weeks.
|
Anti-tumor activity of the pazopanib/cisplatin combination will be carried out by the determination of the objective response rate according to RECIST criteria version 1.1.
|
At baseline and every 6 weeks.
|
To characterize the pharmacokinetic (PK) profile of the combination pazopanib and cisplatin
Time Frame: Cycles 1 and 2
|
The objective of the pharmacokinetics is to investigate the interactions between cisplatin IV and pazopanib
|
Cycles 1 and 2
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Veronique DIERAS, MD, Institut Curie
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GEP 07/0908 - PACIFIK
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Cancer
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Cedars-Sinai Medical CenterRecruitingNeoplasms | Cancer | Cancer, MetastaticUnited States
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Oslo University HospitalVestre Viken Hospital Trust; University Hospital of North Norway; Ostfold Hospital... and other collaboratorsRecruitingCancer MetastaticNorway
Clinical Trials on cisplatin
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Insmed IncorporatedCompletedOsteosarcoma MetastaticUnited States
-
Privo TechnologiesNational Cancer Institute (NCI)CompletedOral Squamous Cell CarcinomaUnited States
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Cedars-Sinai Medical CenterRecruitingHPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsActive, not recruitingNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck NeoplasmChina